The relationship between anxiety and vaginal-related sexual health in postmenopausal breast cancer survivors on aromatase inhibitors therapies: a cross sectional study.
The relationship between anxiety and vaginal-related sexual health in postmenopausal breast cancer survivors on aromatase inhibitors therapies: a cross sectional study.
复制标题
接受芳香酶抑制剂治疗的绝经后乳腺癌幸存者的焦虑与阴道相关性健康之间的关系：一项横断面研究。
DOI：
10.1007/s10549-023-06981-5
复制
发表时间：
2023
影响因子：
3.8
通讯作者：
Mao,JunJ
中科院分区：
文献类型：
--
作者：
Bryl,Karolina;Chimonas,Susan;Li,Xiaotong;Li,SusanQ;Mao,JunJ
性健康问题和焦虑是乳腺癌幸存者的破坏性症状;然而，对芳香化酶抑制剂治疗的绝经后乳腺癌幸存者的这些症状知之甚少。本研究的目的是确定焦虑和阴道相关的性健康问题之间的关系，在此population.MethodsWe分析的横断面数据从一个队列研究的绝经后妇女乳腺癌幸存者接受芳香化酶抑制剂。阴道相关的性健康问题与乳腺癌预防试验症状检查表进行了评估。焦虑采用医院焦虑抑郁量表中的焦虑分量表进行评定。我们采用多变量Logistic回归评估焦虑和阴道相关的性健康之间的关系调整临床和社会人口学variables.ResultsAmong 974例患者，305（31.3%）报告焦虑和403（41.4%）阴道相关的性健康问题。与无焦虑的患者相比，有边缘焦虑和临床异常焦虑的患者报告阴道相关性健康问题的发生率更高（分别为36.8%对49%和55.7%，p< 0.001）。在校正临床和社会人口学因素的多变量分析中，异常焦虑与较高的阴道相关性健康问题发生率相关，校正比值比为1.69（95%CI 1.06- 2.70，p = 0.03）。阴道相关性健康问题更常见的患者年龄在65岁以下，接受紫杉烷为基础的化疗，报告抑郁症，已婚/与伴侣生活（p< 0.05）。由于性健康问题的治疗是有限的，结果表明，焦虑的心理社会干预可能会被调整，同时解决性健康需求。
PurposeSexual health problems and anxiety are disruptive symptoms in breast cancer survivors; however, little is known about these symptoms in postmenopausal breast cancer survivors on aromatase inhibitors therapies. This study aimed to determine the relationship between anxiety and vaginal-related sexual health problems in this population.MethodsWe analyzed cross-sectional data from a cohort study of postmenopausal women breast cancer survivors receiving aromatase inhibitors. Vaginal-related sexual health problems were assessed with the Breast Cancer Prevention Trial Symptom Checklist. Anxiety was assessed with the anxiety subscale of the Hospital Anxiety and Depression Scale. We used multivariable logistic regression to evaluate relationship between anxiety and vaginal-related sexual health adjusted for clinical and sociodemographic variables.ResultsAmong 974 patients, 305 (31.3%) reported anxiety and 403 (41.4%) had vaginal-related sexual health problems. Compared to those without anxiety, patients with borderline and clinically abnormal anxiety reported higher rates of vaginal-related sexual health problems (36.8% vs. 49% and 55.7% respectively,p< 0.001). In multivariate analyses adjusted for clinical and sociodemographic factors, abnormal anxiety was associated with a higher rate of vaginal-related sexual health problems, with adjusted odds ratios of 1.69 (95% CI 1.06–2.70,p= 0.03). Vaginal-related sexual health problems were more frequent among patients who were under 65 years of age, received Taxane-based chemotherapy, reported depression, and were married/living with a partner (p< 0.05).ConclusionAmong postmenopausal breast cancer survivors on aromatase inhibitors therapies, anxiety was significantly associated with vaginal-related sexual health problems. As treatments for sexual health problems are limited, results suggest that psychosocial interventions for anxiety could potentially be adapted to simultaneously address sexual health needs.
登录
查看更多内容
DOI：
10.1016/0006-291x(73)90949-2
发表时间：
1973-01-01
影响因子：
3.1
作者：
BAUGH, CM;KRUMDIECK, CL;NAIR, MG
通讯作者：
NAIR, MG
10-脱氮氨基蝶呤和10-乙基-10-脱氮氨基蝶呤的聚-γ-谷氨酰代谢物的合成和生物学评价。
影响因子：
7.3
作者：
Nair,MG;Nanavati,NT;Kumar,P;Gaumont,Y;Kisliuk,RL
通讯作者：
Kisliuk,RL
影响因子：
11.2
作者：
J. Hyams;M. Donaldson;J. Metcalf;R. Root
通讯作者：
R. Root
影响因子：
--
作者：
ABRAMSON, SB;WEISSMANN, G
通讯作者：
WEISSMANN, G
影响因子：
15.9
作者：
COHEN, HJ;CHOVANIEC, ME
通讯作者：
CHOVANIEC, ME